These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30522045)

  • 21. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1α-Dependent Inhibition of Wnt/β-Catenin.
    Cui L; Zhao J; Liu J
    Am J Med Sci; 2018 Mar; 355(3):274-280. PubMed ID: 29549930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
    Li N; Zhang Y; Wu T; Li M
    Ai Zheng; 2009 Aug; 28(8):838-43. PubMed ID: 19664330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells.
    Nawara HM; M Afify S; Hassan G; Zahra MH; Atallah MN; Mansour H; Abu Quora HA; Alam MJ; Osman A; Kakuta H; Hamada H; Seno A; Seno M
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.
    Allison SE; Chen Y; Petrovic N; Zhang J; Bourget K; Mackenzie PI; Murray M
    Biochem Pharmacol; 2017 Nov; 143():79-89. PubMed ID: 28756208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.
    Ahmed D; de Verdier PJ; Ryk C; Lunqe O; Stål P; Flygare J
    Pharmacol Res Perspect; 2015 Oct; 3(5):e00171. PubMed ID: 26516583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
    Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
    Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
    BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
    Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
    Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
    Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
    Kuo YC; Lin WC; Chiang IT; Chang YF; Chen CW; Su SH; Chen CL; Hwang JJ
    Biomed Pharmacother; 2012 Feb; 66(1):12-20. PubMed ID: 22265104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of apoptosis in human renal cell carcinoma cells by vitamin E succinate in caspase-independent manner.
    Wu XX; Kakehi Y; Jin XH; Inui M; Sugimoto M
    Urology; 2009 Jan; 73(1):193-9. PubMed ID: 18692875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiosensitization by the combination of SR-2508 and paclitaxel in hypoxic human tumor cells in vitro.
    Jin C; Bai L; Guo G
    J Radiat Res; 2007 May; 48(3):179-85. PubMed ID: 17420623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
    Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy.
    Sui M; Dziadyk JM; Zhu X; Fan W
    Clin Cancer Res; 2004 Jul; 10(14):4848-57. PubMed ID: 15269161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.
    Shang D; Xian S; Han T; Li X; Liu Y
    J BUON; 2017; 22(4):1038-1045. PubMed ID: 28952225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.